Hikma’s sluggish run continued into the third quarter (trading update), the key highlight of which was the second successive guidance downgrade for the generics business – FY 15 revenue is now expected to be $150m from the previously indicated range of $175-200m. Of greater importance, however, was the profit warning, with management now guiding for the segment’s FY 15 operating margin to be in the ‘high twenties’, nearly half of its FY 14 operating margin of 52%
27 Nov 2015
Currency and operating weakness continue to disappoint but recovery on the cards
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Currency and operating weakness continue to disappoint but recovery on the cards
Hikma Pharmaceuticals Plc (HIK:LON) | 1,803 252.4 0.8% | Mkt Cap: 4,001m
- Published:
27 Nov 2015 -
Author:
Jyoti Prakash -
Pages:
2
Hikma’s sluggish run continued into the third quarter (trading update), the key highlight of which was the second successive guidance downgrade for the generics business – FY 15 revenue is now expected to be $150m from the previously indicated range of $175-200m. Of greater importance, however, was the profit warning, with management now guiding for the segment’s FY 15 operating margin to be in the ‘high twenties’, nearly half of its FY 14 operating margin of 52%